New Risk • Jul 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹5.6m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (₹1.0m revenue, or US$11k). Market cap is less than US$10m (₹147.2m market cap, or US$1.55m). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change). Reported Earnings • May 31
Full year 2026 earnings released: ₹0.91 loss per share (vs ₹1.04 loss in FY 2025) Full year 2026 results: ₹0.91 loss per share (improved from ₹1.04 loss in FY 2025). Net loss: ₹7.40m (loss narrowed 13% from FY 2025). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Tillkännagivande • May 25
Ortin Global Limited to Report Q4, 2026 Results on May 30, 2026 Ortin Global Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026 Reported Earnings • Feb 15
Third quarter 2026 earnings released: ₹0.07 loss per share (vs ₹0.13 loss in 3Q 2025) Third quarter 2026 results: ₹0.07 loss per share (improved from ₹0.13 loss in 3Q 2025). Net loss: ₹532.0k (loss narrowed 50% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year. Tillkännagivande • Feb 05
Ortin Global Limited to Report Q3, 2026 Results on Feb 14, 2026 Ortin Global Limited announced that they will report Q3, 2026 results on Feb 14, 2026 New Risk • Dec 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.2m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (₹1.7m revenue, or US$19k). Market cap is less than US$10m (₹116.8m market cap, or US$1.30m). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). Reported Earnings • Nov 17
Second quarter 2026 earnings released: ₹0.62 loss per share (vs ₹0.58 loss in 2Q 2025) Second quarter 2026 results: ₹0.62 loss per share (further deteriorated from ₹0.58 loss in 2Q 2025). Net loss: ₹5.03m (loss widened 6.4% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year. Tillkännagivande • Nov 08
Ortin Global Limited to Report Q2, 2026 Results on Nov 14, 2025 Ortin Global Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Tillkännagivande • Sep 08
Ortin Global Limited, Annual General Meeting, Sep 30, 2025 Ortin Global Limited, Annual General Meeting, Sep 30, 2025, at 16:00 Indian Standard Time. Tillkännagivande • Aug 27
Ortin Global Limited Approves Board Appointments Ortin Global Limited at its EGM held on August 25, 2025 approved appointment of Mr. Sarang Balbhimrao Patodekar as chairperson and independent director of the company, Mr. Ajay Vishwakarma as an independent director of the company, Ms' Mounika Pammi as an independent director of the company, Mr. prashant prakash Sawant as a director and Whole-time director of the company and Mrs. Prakruti Prashant Sawant as a director and whole-time director of the company. Reported Earnings • Aug 16
First quarter 2026 earnings released: ₹0.22 loss per share (vs ₹0.13 loss in 1Q 2025) First quarter 2026 results: ₹0.22 loss per share (further deteriorated from ₹0.13 loss in 1Q 2025). Net loss: ₹1.75m (loss widened 70% from 1Q 2025). New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹4.1m free cash flow). Earnings have declined by 60% per year over the past 5 years. Revenue is less than US$1m (₹3.8m revenue, or US$44k). Market cap is less than US$10m (₹122.1m market cap, or US$1.39m). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change). Tillkännagivande • Aug 09
Ortin Global Limited to Report Q1, 2026 Results on Aug 14, 2025 Ortin Global Limited announced that they will report Q1, 2026 results on Aug 14, 2025 Board Change • Aug 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Additional Non-Executive Director Shashikant Igave is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • May 28
Full year 2025 earnings released: ₹1.04 loss per share (vs ₹9.89 loss in FY 2024) Full year 2025 results: ₹1.04 loss per share (improved from ₹9.89 loss in FY 2024). Revenue: ₹3.84m (down 82% from FY 2024). Net loss: ₹8.46m (loss narrowed 90% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. Tillkännagivande • May 19
Ortin Global Limited to Report Q4, 2025 Results on May 26, 2025 Ortin Global Limited announced that they will report Q4, 2025 results on May 26, 2025 New Risk • Mar 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹58m free cash flow). Earnings have declined by 64% per year over the past 5 years. Revenue is less than US$1m (₹4.4m revenue, or US$51k). Market cap is less than US$10m (₹100.3m market cap, or US$1.16m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Reported Earnings • Feb 14
Third quarter 2025 earnings released: ₹0.13 loss per share (vs ₹3.43 loss in 3Q 2024) Third quarter 2025 results: ₹0.13 loss per share (improved from ₹3.43 loss in 3Q 2024). Revenue: ₹335.0k (down 75% from 3Q 2024). Net loss: ₹1.07m (loss narrowed 96% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance. Tillkännagivande • Feb 07
Ortin Global Limited to Report Q3, 2025 Results on Feb 12, 2025 Ortin Global Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 15
Second quarter 2025 earnings released: ₹58.00 loss per share (vs ₹1.38 loss in 2Q 2024) Second quarter 2025 results: ₹58.00 loss per share. Revenue: ₹525.0k (down 80% from 2Q 2024). Net loss: ₹4.72m (loss narrowed 58% from 2Q 2024). Tillkännagivande • Nov 05
Ortin Global Limited to Report Q2, 2025 Results on Nov 13, 2024 Ortin Global Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Tillkännagivande • Sep 13
Ortin Global Limited, Annual General Meeting, Sep 30, 2024 Ortin Global Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2025 earnings released: ₹0.13 loss per share (vs ₹0.02 profit in 1Q 2024) First quarter 2025 results: ₹0.13 loss per share (down from ₹0.02 profit in 1Q 2024). Revenue: ₹2.11m (down 87% from 1Q 2024). Net loss: ₹1.03m (down ₹1.19m from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. New Risk • Aug 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 59% per year over the past 5 years. Revenue is less than US$1m (₹21m revenue, or US$252k). Market cap is less than US$10m (₹162.6m market cap, or US$1.94m). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change). Tillkännagivande • Aug 07
Ortin Global Limited to Report Q1, 2025 Results on Aug 13, 2024 Ortin Global Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Tillkännagivande • Jul 18
Ortin Laboratories Limited Announces Resignation of Divya Purswani as Company Secretary and Compliance Officer Ortin Laboratories Limited announced that Mrs. Divya Purswani has resigned from the post of company secretary and compliance officer of the company with effect from 18 July 2024 (After close of Business hours) due to her personal reasons. Reported Earnings • Jun 04
Full year 2024 earnings released: ₹9.89 loss per share (vs ₹0.12 loss in FY 2023) Full year 2024 results: ₹9.89 loss per share (further deteriorated from ₹0.12 loss in FY 2023). Revenue: ₹22.8m (down 62% from FY 2023). Net loss: ₹80.4m (loss widened ₹79.5m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Tillkännagivande • May 24
Ortin Laboratories Limited to Report Q4, 2024 Results on May 30, 2024 Ortin Laboratories Limited announced that they will report Q4, 2024 results on May 30, 2024 Reported Earnings • Feb 14
Third quarter 2024 earnings released: ₹3.43 loss per share (vs ₹0.56 profit in 3Q 2023) Third quarter 2024 results: ₹3.43 loss per share (down from ₹0.56 profit in 3Q 2023). Revenue: ₹1.37m (down 88% from 3Q 2023). Net loss: ₹27.9m (down ₹32.5m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Tillkännagivande • Feb 09
Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance Officer The Board of Directors of Ortin Laboratories Limited at its meeting held on 9 February, 2024 has considered and approved the Appointment of Ms. Divya Purswani as Company Secretary and Compliance Officer of the Company with effect from February 09, 2024. Ms. Divya Purswani is a qualified Company Secretary, having working experience of around 2 years in the area of corporate laws and secretarial matters. Tillkännagivande • Feb 07
Ortin Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024 Ortin Laboratories Limited announced that they will report Q3, 2024 results on Feb 13, 2024 Buy Or Sell Opportunity • Jan 29
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 26% to ₹22.00. The fair value is estimated to be ₹18.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 65% over the last 3 years. Meanwhile, the company became loss making. Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pottur Sujatha was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Nov 16
Second quarter 2024 earnings released Second quarter 2024 results: ₹1.38 loss per share. Revenue: ₹2.65m (down 66% from 2Q 2023). Net loss: ₹11.2m (down ₹12.0m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. Tillkännagivande • Nov 12
Ortin Laboratories Limited Announces Executive Changes Ortin Laboratories Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer with effect from 10 November 2023, due to his personal reasons. (After close of Business hours). Mr. S. Murali Krishna Murthy, Managing Director will act as the Compliance Officer of the Company till the appointment of new Company Secretary and Compliance Officer. Tillkännagivande • Oct 11
Ortin Laboratories Limited Appointment of Harish Sharma as Company Secretary Ortin Laboratories Limited announced at the board meeting held on October 10, 2023, approved Appointment of Mr. Harish Sharma as Company Secretary and Compliance Officer of the Company with effect from 10.10.2023. Mr. Harish Sharma is a qualified Company Secretary, having working experience of around 4.5 years in the area of corporate laws and secretarial matters. Tillkännagivande • Sep 07
Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023 Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time. Reported Earnings • Aug 16
First quarter 2024 earnings released First quarter 2024 results: EPS: ₹0.02. Revenue: ₹15.7m (down 40% from 1Q 2023). Net income: ₹164.0k (up ₹4.43m from 1Q 2023). Profit margin: 1.0% (up from net loss in 1Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Tillkännagivande • Aug 05
Ortin Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023 Ortin Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Tillkännagivande • Jul 12
Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories Limited Ortin Laboratories Limited announced that Drugs Control Administration, Government of Telangana vide its Order dated 03 July 2023 received by the Company on 11 July 2023 has cancelled the Company's Manufacturing License effective from July 11, 2023 forwant of upgradation of manufacturing facilities, infrastructure and recruiting expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act, 1940 & rules made there under. Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any: Could not upgrade the manufacturing facilities, infrastructure and expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act. 1940. Production of medicines is stopped and as a result there will be monetary impact to the tune of 75% of the turnover which is approximately INR 60 million. There is no other penalty involved or imposed on the company. Tillkännagivande • Jun 14
Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance Officer Ortin Laboratories Limited informed that Mr. Nitesh Kumar Sharma has resigned from the post of Company Secretary and Compliance officer of the company with effect from June 12, 2023 (After close of Business hours). Mr. S. Murali Krishna Murthy, Managing Director will act as the Compliance Officer of the Company till the appointment of new Company Secretary and Compliance Officer. New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (₹61m revenue, or US$735k). Market cap is less than US$10m (₹186.9m market cap, or US$2.27m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Reported Earnings • Jun 03
Full year 2023 earnings released: ₹0.08 loss per share (vs ₹0.49 loss in FY 2022) Full year 2023 results: ₹0.08 loss per share (improved from ₹0.49 loss in FY 2022). Revenue: ₹60.6m (down 26% from FY 2022). Net loss: ₹669.0k (loss narrowed 83% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.11 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹0.56 (up from ₹0.11 loss in 3Q 2022). Revenue: ₹11.7m (down 30% from 3Q 2022). Net income: ₹4.56m (up ₹5.46m from 3Q 2022). Profit margin: 39% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Tillkännagivande • Feb 01
Ortin Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023 Ortin Laboratories Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2023 Reported Earnings • Nov 20
Second quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.07 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.01. Revenue: ₹7.87m (down 66% from 2Q 2022). Net income: ₹808.0k (up 50% from 2Q 2022). Profit margin: 10% (up from 2.3% in 2Q 2022). The increase in margin was driven by lower expenses. Reported Earnings • Aug 19
First quarter 2023 earnings released: ₹0.05 loss per share (vs ₹0.11 profit in 1Q 2022) First quarter 2023 results: ₹0.05 loss per share (down from ₹0.11 profit in 1Q 2022). Revenue: ₹26.2m (up 32% from 1Q 2022). Net loss: ₹4.27m (down ₹5.18m from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Reported Earnings • Jun 02
Full year 2022 earnings released: ₹0.49 loss per share (vs ₹1.16 profit in FY 2021) Full year 2022 results: ₹0.49 loss per share (down from ₹1.16 profit in FY 2021). Revenue: ₹84.3m (up 2.5% from FY 2021). Net loss: ₹3.99m (down 142% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Executive Departure • Dec 05
Whole Time Director Sanka Mohan Murthy has left the company On the 26th of November, Sanka Mohan Murthy's tenure as Whole Time Director ended after 10.8 years in the role. As of September 2021, Sanka Mohan still personally held only 13.62k shares (₹367k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Oct 08
Investor sentiment improved over the past week After last week's 17% share price gain to ₹30.85, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 14% over the past three years. Reported Earnings • Jul 10
Full year 2021 earnings released: EPS ₹1.16 (vs ₹0.69 loss in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹82.2m (down 96% from FY 2020). Net income: ₹9.46m (up ₹15.1m from FY 2020). Profit margin: 12% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improved over the past week After last week's 27% share price gain to ₹36.30, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹25.35, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 35% over the past three years. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 27% share price gain to ₹32.60, the stock is trading at a trailing P/E ratio of 22x, up from the previous P/E ratio of 17.3x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 19%. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 16% share price gain to ₹30.00, the stock is trading at a trailing P/E ratio of 20.9x, up from the previous P/E ratio of 18x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 8.3%. Is New 90 Day High Low • Dec 31
New 90-day high: ₹30.00 The company is up 54% from its price of ₹19.45 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Valuation Update With 7 Day Price Move • Dec 03
Market bids up stock over the past week After last week's 17% share price gain to ₹25.60, the stock is trading at a trailing P/E ratio of 18x, up from the previous P/E ratio of 15.4x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 35%. Is New 90 Day High Low • Nov 18
New 90-day high: ₹23.15 The company is up 4.0% from its price of ₹22.30 on 20 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. 
